Diffuse Large B Cell Lymphoma Refractory

19 clinical trials · Condition

Record	Firm	Date
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT05121103)	Epizyme, Inc.	2022-05-31
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (NCT04703686)	The Lymphoma Academic Research Organisation	2021-03-30
Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (NCT03795571)	The First Affiliated Hospital with Nanjing Medical University	2019-01-01
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT03589469)	ADC Therapeutics S.A.	2018-08-01
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL (NCT03367143)	Ruijin Hospital	2016-12-01
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma (NCT02594163)	Seagen Inc.	2015-10-01
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT02142049)	Pharmacyclics LLC.	2014-05-01
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (NCT01805557)	Fondazione Italiana Linfomi - ETS	2013-02-04

Every clearance here is in the API, with alerts when new ones post.